News8 months ago
AIM ImmunoTech Reports Q1 2024 Financial Results and Provides Corporate Update
AIM ImmunoTech Inc. Continued execution of Ampligen® clinical development programs and growing pool of positive data across multiple high-value indications Company will hold conference call and...
